BLT Stock Overview
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity.
BLIS Technologies Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$0.026|
|52 Week High||NZ$0.053|
|52 Week Low||NZ$0.025|
|1 Month Change||-7.14%|
|3 Month Change||-13.33%|
|1 Year Change||-46.94%|
|3 Year Change||-45.83%|
|5 Year Change||52.94%|
|Change since IPO||-97.37%|
Recent News & Updates
BLIS Technologies (NZSE:BLT) Is In A Strong Position To Grow Its BusinessDec 05
Calculating The Intrinsic Value Of BLIS Technologies Limited (NZSE:BLT)Mar 08
BLIS Technologies Limited (NZSE:BLT) Insiders Have Been SellingFeb 09
BLIS Technologies Limited (NZSE:BLT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?Jan 21
I Ran A Stock Scan For Earnings Growth And BLIS Technologies (NZSE:BLT) Passed With EaseJan 03
Should You Use BLIS Technologies's (NZSE:BLT) Statutory Earnings To Analyse It?Dec 15
Introducing BLIS Technologies (NZSE:BLT), The Stock That Soared 371% In The Last Three YearsNov 28
|BLT||NZ Pharmaceuticals||NZ Market|
Return vs Industry: BLT underperformed the NZ Pharmaceuticals industry which returned -23.8% over the past year.
Return vs Market: BLT underperformed the NZ Market which returned -11.9% over the past year.
|BLT Average Weekly Movement||6.9%|
|Pharmaceuticals Industry Average Movement||9.6%|
|Market Average Movement||4.2%|
|10% most volatile stocks in NZ Market||6.7%|
|10% least volatile stocks in NZ Market||2.9%|
Stable Share Price: BLT is more volatile than 90% of NZ stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BLT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of infants and children, as well as for improving bad breath; and BLIS M18 for promoting the bacterial balance for dental health. Its product portfolio consists of DailyDefence, a daily probiotic to support throat immunity; DailyDefence Junior, a daily powder formulation to support ear, nose, and throat health of infants and small children; ThroatGuard PRO to give immunity support to help protect against winter ills; ElitePRO, a suite of WADA tested products for athletes; and TravelProtect to help support the immune system when travelling.
BLIS Technologies Limited Fundamentals Summary
|BLT fundamental statistics|
Is BLT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLT income statement (TTM)|
|Cost of Revenue||NZ$2.09m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.002|
|Net Profit Margin||-27.43%|
How did BLT perform over the long term?See historical performance and comparison